Summary
C3H/He mice were injected i.v. with heavily X-irradiated syngeneic X5563 tumor cells three times at 4-day intervals. This regimen resulted in the abrogation of the potential to generate X5563 tumor-specific T cell-mediated immunity as inducd by i.d. inoculation of viable X5563 tumor cells followed by surgical resection of the tumor, representing the tolerance induction. Although such a tumor-specific tolerant state was long-lasting, the recovery of anti-X5563 effector T cell responses was observed when the above ordinary immunization procedure was performed 6 months after the tolerance induction. The present study investigated whether the recovery from the tolerance can be accelerated by applying a helper-effector T-T cell interaction model in which enhanced anti-X5563 immunity is obtained by priming mice with BCG and by immunizing X5563 tumor cells modified with BCG cross-reactive MDP hapten (designated as L4-MDP) in the presence of anti-L4-MDP helper T cells preinduced with BCG. The results demonstrated that BCG-primed mice which received the tolerance regimen failed to generate anti-X5563 immunity when the ordinary immunization was performed 2 or 3 months after the tolerance induction. In contrast, the immunization of BCG-primed and X5563-tolerant mice with L4-MDP-coupled X5563 tumor cells at comparable timing to that of the ordinary immunization were capable of generating potent X5563-specific in vivo protective T cell-mediated immunity. As control groups, BCG-primed or unprimed tolerant mice did not develop anti-X5563 immunity when immunized with L4-MDP-uncoupled or L4-MDP-coupled tumor cells, respectively. These results indicate that immunization of BCG-primed, tumor-tolerant mice with L4-MDP-modified tumor cells results in accelerated recovery from the tumor tolerance.
Similar content being viewed by others
References
Bowen JG, Robin RA, Baldin RW (1975) Serum factors modifying cell mediated immunity to rat hepatoma D23 correlated with tumor growth. Int J Cancer 15:640
Bradley SM, Morrissey PJ, Sharrow SO, Singer A (1982) Tolerance of thymocytes to allogeneic I region determinants encountered prethymically. Evidence for expression of anti-Ia receptors by T cell precursors before their entry into the thymus. J Exp Med 155:1638
Chervenak R, Cohen JJ, Miller SD (1983) Clonal abortion of bone marrow T cell precursors. T cells acquire specific antigen reactivity prethymically. J Immunol 131:1688
Cohn ML, Scott DW (1979) Functional differentiation of T cell precursors. I. Parameters of carrier specific tolerance in murine helper T cell precursors. J. Immunol 123:2083
Embleton MJ (1976) Influence of cell-free Tumor-associated antigen preparations on the development of immunity to chemically induced rat tumors. Int J Cancer 18:622
Feldman JD (1972) Immunilogical enhancement: A study of blocking antibodies. Adv Immunol 15:167
Fujimoto S, Greene MI, AG Sehon (1976) Regulation of the immune response to tumor antigens. I. Immunosuppressor cells in tumor-bearing hosts. J Immunol 116:791
Fujiwara H, Shearer GM (1981) Suppressive effect of X-irradiated tumor cell presensitization on the induction of syngeneic tumor immunity. II. Opposite effects of intravenous administration of TNP-conjugated tumor cells on the development of anti-tumor and anti-TNP-self cytotoxix effector cells. Cell Immunol 59:181
Fujiwara H, Hamaoka T, Kitagawa M (1978) Suppressive effect of pretreatment with X-irradiated tumor cells on the induction of syngeneic murine tumor system. I. Suppressive versus sensitizing effect on the same pretreatment in 2 tumor systems with different immune responses. Gann 69:793
Fujiwara H, Hamaoka T, Shearer GM, Yamamoto H, Terry WD (1980) The augmentation of in vitro and in vivo tumor-specific T cell-mediated immunity by amplifier T lymphocytes. J Immunol 124:863
Fujiwara H, Tsuchida T, Mizuochi T, Kohmo, Hamaoka T (1981) Suppresive effect of X-irradiated tumor cell presensitization on the induction of syngeneic tumor immunity. III. The mechanism of specific suppression in effector T cell clones against tumor-associated transplantation antigens. Gann 72:732
Fujwara H, Fukuzawa M, Yoshioka T, Nakajima H, Hamaoka T (1984) The role of tumor-specific Lyt-1+2− T cells in eradicating tumor cells in vivo. I. Lyt-1+2− T cells do not necessarily require recruitment of host's cytotoxic T cell precursors for implementation of in vivo immunity. J Immunol 133:1671
Fujiwara H, Moriyama Y, Suda T, Tsuchida T, Shearer GM, Hamaoka T (1984) Enhanced TNP-reactive helper T cell activity and its utilization in the induction of amplified tumor immunity which results in tumor regression. J Immunol 132:1571
Fujiwara H, Sato S, Kosugi A, Fukuzawa M, Hamaoka T (1987) Studies on the recovery from tolerance to tumor antigens. I. Bone marrow cells from tolerant hosts are not rendered tolerant, but provide potential to reconstitute tumor-specific effector T cell clones. Cancer Immunol Immunother 24:113–120
Fukuzawa M, Fujiwara H, Yoshioka T, Itoh K, Hamoka T (1984) Effector cell analysis of tumor cell rejection in vivo in two syngeneic tumor systems exhibiting distinct in vitro cytotoxic mechanism. Gann 75:912
Hamaoka T, Fujiwara H, Teshima K, Aoki H, Yamamoto H, Kitagawa M (1979) Regulatory function of hapten-reactive helper and suppressor T lymphocytes. III. Amplification of generation of tumor-specific cytotoxic effector T lymphocytes by suppressor T cell-depleted hapten-reactive T lymphocytes. J Exp Med 149:185
Hamaoka T, Takai Y, Kosugi A, Mizushima Y, Shima J, Kusama T, Fujiwara H (1985). The augmentation of tumor-specific immunity by utilizing haptenic muramyl dipeptide (MDP) derivatives. I. Synthesis of a novel haptenic MDP derivative cross-reactive with Bacillus Calmette Guerin and its application to enhanced induction of tumor immunity. Cancer Immuno Immunother 20:183
Hellstrom KE, Hellstrom I (1974) Lymphocyte-mediated cytotoxicity and blocking serum activity to tumor antigens. Adv Immunol 18:209
Morrissey PJ, Kruisbeek AM, Sharrow SO, Singer A (1982) Tolerance of thymic cytotoxic T lymphocytes to allogeneic H-2 determinants encountered prethymically: evidence for expression of anti-H-2 receptors prior to entry into the thymus. Proc Natl Acad Sci USA 79:2003
Kamo I, Friedman H (1977) Immunosuppression and the role of suppressive factors in cancer. Adv Cancer Res 25:271
Kuhara T, Hosono M, Fujiwara M (1981) Studies on the restistance to tolerance induction against human IgG in DDD mice. Cell immunol 57:377
Padarathsingh ML, McCoy JL Dean, Lewis JH, Northing DD, Law JW and LW (1977) Examination of general and tumor-specific cell-mediated immune responses in mice bearing progressively growing plasmacytomas. J. Nal Cancer Inst 58:1701
Sanfilippo F, Cohn ML, Scott DW (1976) Effect of carrier-specific tolerance on the generation of helper cell function. Eur J Immunol 6:742
Shimizu Y, Fujiwara H, Ueda S, Wakamiya N, Kato S, Hamaoka T (1984) The augmentation of tumor-specific immunity by virus-help. II. Enhanced induction of cytotoxic T lymphocyte and antibody responses to tumor antigens by vaccinia-reactive helper T cell. Eur J Immunol 14:839
Author information
Authors and Affiliations
Additional information
This work was supported by the Special Project Cancer-Bioscience from the Ministry of Education, Science and Culture, Japan
Abbreviations used: MDP, muramyl dipeptide; BCG, Bacillus Calmette Guerin; C, complement
Rights and permissions
About this article
Cite this article
Sato, S., Fujiwara, H., Kosugi, A. et al. Studies on the recovery from tolerance to tumor antigens. Cancer Immunol Immunother 24, 121–126 (1987). https://doi.org/10.1007/BF00205588
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00205588